The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  66 (2024)
Volume  65 (2023)
Volume  64 (2022)
Volume  63 (2021)
Volume  62 (2020)
Volume  61 (2019)
Volume  60 (2018)
Volume  59 (2017)
Volume  58 (2016)
Volume  57 (2015)
Volume  56 (2014)
Volume  55 (2013)
Volume  54 (2012)
Volume  53 (2011)
Volume  52 (2010)
Related articles

VOLUME 66 , ISSUE 3 ( July-September, 2024 ) > List of Articles

CASE SERIES

Case Series on Rifampicin-induced Thrombocytopenia with Daily Regimen: Clinical Insights and Management Strategies

Eshutosh Chandra, Amitesh Gupta, Shipra Anand, Irshad Ahmad, Pooja Narwal, Naresh Kumar

Keywords : Adverse effect, Immune-mediated reaction, Rifampicin, Thrombocytopenia, Tuberculosis

Citation Information : Chandra E, Gupta A, Anand S, Ahmad I, Narwal P, Kumar N. Case Series on Rifampicin-induced Thrombocytopenia with Daily Regimen: Clinical Insights and Management Strategies. Indian J Chest Dis Allied Sci 2024; 66 (3):106-109.

DOI: 10.5005/jp-journals-11007-0126

License: CC BY-NC 4.0

Published Online: 19-11-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Thrombocytopenia, a rare but serious complication of rifampicin treatment, underscores the importance of timely intervention to prevent adverse outcomes. This article offers a detailed exploration of rifampicin-induced thrombocytopenia, shedding light on its causes, symptoms, diagnosis, and treatment options. Through a blend of research insights and real-life cases, we emphasize the crucial role of healthcare providers in recognizing and addressing this condition promptly. By advocating for increased awareness and vigilant monitoring, we aim to ensure the safety and well-being of patients undergoing anti-tuberculosis treatment.

PDF Share
  1. World Health Organization. World Health Organization Global Tuberculosis Report 2020. [online] Available from: https://www.who.int/publications/i/item/9789240013131. [Last accessed October, 2024].
  2. Aquinas M. Short-course therapy for tuberculosis. Drugs 1982;24(2):118–132. DOI: 10.2165/00003495-198224020-00002.
  3. Blajchman MA, Lowry RC, Petil JE, et al. Rifampicin induced thrombocytopenia. Br Med J 1970;3(5713):24–26. DOI: 10.1136/bmj.3.5713.24.
  4. BanuRekha VV, Adhilakshmi AR, Jawahar MS. Rifampicin-induced acute thrombocytopenia. Lung India 2005;22(4):122–124. Available from: http://eprints.nirt.res.in/id/eprint/683.
  5. George JN, Raskob GE, Shah SR, et al. Drug induced thrombocytopenia a systematic review of published case reports. Ann Intern Med 1998;129(11):886–890. DOI: 10.7326/0003-4819-129-11_part_1-199812010-00009.
  6. Pool G, Stradling P, Worlledge S. Potentially serious side effects of high dose twice weekly rifampicin. Br Med J 1971;3(5770):343–347. DOI: 10.1136/bmj.3.5770.343.
  7. Ferguson GC. Rifampicin and thrombocytopenia. Br Med J 1971;3(5775):638. DOI: 10.1136/bmj.3.5775.638.
  8. George JN, Raskob GE, Shah SR, et al. Drug induced thrombocytopenia a systematic review of published case reports. Ann Intern Med 1998;129(11):886–890. DOI: 10.7326/0003-4819-129-11_part_1-199812010-00009.
  9. Larbaoui D, Chaulet P, Grosset J, et al. Intermittent treatment of “intractable chronic tuberculosis” by combined rifampicin-ethambutol: Preliminary results of a controlled survey made in Algeria. Rev Tuberc Pneumol (Paris) 1970;34(4):559–566. PMID: 4928583.
  10. Doyle JA. In XX International Tuberculosis Conference, New York. New York: Excerpta Medica; 1969; p. 25.
  11. Bansal R, Sharma PK, Sharma A. A case of thrombocytopenia caused by rifampicin and pyrazinamide. Indian J Pharmacol 2013;45(4):405–407. DOI: 10.4103/0253-7613.114998.
  12. Mehta YS, Jijina FF, Badakere SS, et al. Rifampicin-induced immune thrombocytopenia. Tuber Lung Dis 1996;77(6):558–562. DOI: 10.1016/s0962-8479(96)90056-8.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.